Randomized Phase II/III Study of Nivolumab plus Ipilimumab plus Sargramostim versus Nivolumab plus Ipilimumab in Patients with Unresectable Stage III or Stage IV Melanoma

IRB/UVA Tracking #
18569
Contact
Contact Phone
Phase
II/III
Primary purpose
Treatment
Cancer PI
Elizabeth M Gaughan
Status
OPEN TO ACCRUAL
Ages
Adult